3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Gynecologic
3
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Interventions
Bevacizumab
21
Paclitaxel
19
Carboplatin
15
pembrolizumab
14
Specimen Handling
14
liposomal doxorubicin
12
Magnetic Resonance Spectroscopy
12
Cyclophosphamide
11
olaparib
10
Gemcitabine
10
fludarabine
9
Topotecan
8
Biopsy
8
Fulvestrant
7
niraparib
6
Nivolumab
6
palbociclib
5
Taxes
5
Immunoglobulin G
5
Doxorubicin
5
Disulfides
5
aldesleukin
4
trastuzumab deruxtecan
3
mirvetuximab soravtansine
3
binimetinib
3
Oxaliplatin
3
Cisplatin
3
AZD5305
3
1-dodecylpyridoxal
3
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled